| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f5fd3ed7ba1ebd1a84450c3bddc5ef11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_06d63a2c40177310838f1e5d7cc16b21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fdaa64756184e715af6cb25ebc318917
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_71c07e6cdbcda1092a3f5f1b63ead5b1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6764f05a0538233251ff8eb1366b2dca |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2012-05-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_880e640ee133e422286e266b95c90d30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_446b68b4df2d6194eb840960632c13df
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ff92e161d41b4610114af8234b1e71c8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_13ce41692e779f02230d25a0ae62b6d9 |
| publicationDate |
2013-08-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2012156975-A9 |
| titleOfInvention |
COMBINATIONS OF ANTI ErbB ANTIBODIES FOR THE TREATMENT OF CANCER |
| abstract |
An article-of-manufacture is provided. The article-of-manufacture comprises a packaging material identified for treating cancer, packaging: (i) an anti-EGFR antibody comprising the CDR sequences of anti EGFR 565 (CNCM Deposit Number I-4262); and (ii) an anti-ErbB-2 antibody comprising the CDR sequences of anti ErbB-2 L431 (CNCM Deposit Number I-4115), anti ErbB-2 L26 (CNCM Deposit Number I- 4113) or anti ErbB-2 N12 (CNCM Deposit Number I-4112), or (iii) an anti-EGFR antibody comprising the CDR sequences of anti EGFR 111 (CNCM Deposit Number I-4261); and (iv) an anti-ErbB-2 antibody comprising the CDR sequences of anti ErbB-2 L431 (CNCM Deposit Number I-4115). Also provided are pharmaceutical compositions and methods of using the above antibodies as well as other antibody combinations for the treatment of cancer. |
| priorityDate |
2011-05-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |